Clinical Trial

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
Protocol Amendment History 3 changes
notable Trial sites expanded: 34 -> 39 locations 2026-07-15
notable Trial sites expanded: 31 -> 34 locations 2026-06-24
notable Trial sites expanded: 28 -> 31 locations 2026-05-29
Trial Details
NCT Number NCT05533697
Lead Sponsor ModernaTX, Inc.
Conditions Advanced Solid Tumors
Enrollment 361 participants
Start Date 2022-09-01
Primary Completion 2032-02-18 (estimated)
Study Completion 2032-02-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-14